Last month, Madrigal Pharmaceuticals (NSDQ:MDGL) announced promising preliminary results from an open-label Phase 3 trial from its MAESTRO-NAFLD-1 study focused on Resmetirom. The drug, also known as MGL-3196, appeared to support reducing fat and fibrosis within the liver while also curbing biomarkers associated with inflammation. The data also suggest that the drug reduces LDL cholesterol.…